Background: Major injuries that are caused by trauma and cancer can not be repaired through bone remodeling. The goal of bone regeneration by tissue engineering approaches is to fabricate bone implants in order to restore bone structure and functions. The use of stem cells and polymer scaffolds provides the conditions for tissue regeneration based on tissue engineering. Objective: This study aimed to fabricate a combined matrix of poly(lactide-co-glycolide) (PLGA) and propolis extract, which is a mixture of pollen and beeswax collected by bees from certain plants and has long been used in traditional herbal medicine, to promote the osteogenic differentiation of human adipose-derived mesenchymal stem cells (AD-MSCs). Methods: The scaffold was fabricated through electrospinning and was immersed in a propolis extract solution. Then, AD-MSCs were cultured and differentiated into the osteogenic lineage. The cell viability on the scaffold was evaluated by MTT assay. Osteogenic differentiation of the seeded stem cells was detected by evaluating calcium content, alkaline phosphatase (ALP) activity, and the expression of bone-specific genes. Results: The viability of cells was not affected by propolis-coated and uncoated fabricated scaffolds, while higher calcium content, ALP activity, and expression of RUNX-2, type I collagen, osteocalcin, and osteonectin were observed in cells differentiated on propolis-coated PLGA scaffold on days 7, 14, and 21 of differentiation compared to PLGA scaffold. Conclusion: The results of this study showed that the presence of propolis in the scaffold could lead to better cell attachment and strengthen the osteoinduction process in stem cells.

Allogeneic tissue transplantation is one of the most effective treatments for several diseases and injuries, in particular, malignant and non-malignant hematological conditions. Following this procedure, transplanted tissue encounters various complications, one of the most serious being graft-versus-host disease (GvHD).The management of GvHD directly affects the success of transplantation and the survival rate of the patient; therefore, many studies have focused on GvHD prevention and control. This review briefly explains the transplantation process, causes of graft rejection, and importance of the human leukocyte antigen system.Initially, we address the pathophysiology and immunobiology of GvHD, the cells involved in this complication, the differences between chronic and acute GvHD, and the importance of graft-versusleukemia. Interestingly, various types of immune cells are involved in GvHD pathogenesis. After explaining how these cells affect the GvHD process, we discuss the studies conducted to control and reduce GvHD symptoms.